Last updated: February 19, 2026
This analysis details the scope, claims, and patent landscape surrounding Brazil patent application BR112023026559, concerning a pharmaceutical composition for treating neurodegenerative diseases. The application, filed on December 7, 2023, by Genervon Biopharmaceuticals LLC, seeks protection for a novel therapeutic agent and its uses.
What is the core invention described in BR112023026559?
The patent application BR112023026559 describes a pharmaceutical composition comprising an extract of Hericium erinaceus (Lion's Mane mushroom). The primary active component identified is an extract rich in polysaccharides, specifically beta-glucans, and neurotrophic factors like hericenones and erinacines [1]. The invention claims efficacy in treating and preventing neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). The mechanism of action is attributed to the stimulation of nerve growth factor (NGF) synthesis and the reduction of neuroinflammation [1].
What specific claims are asserted in BR112023026559?
The patent application outlines several claims, broadly categorized into composition claims and use claims.
Composition Claims
- Claim 1: A pharmaceutical composition comprising an extract of Hericium erinaceus. This extract is characterized by a specific polysaccharide content and the presence of hericenones and erinacines. The composition may be formulated for oral administration, such as in capsules, tablets, or granules.
- Claim 2: The pharmaceutical composition of claim 1, wherein the extract is obtained through a specific extraction process detailed in the application, emphasizing high yields of target bioactive compounds.
- Claim 3: The pharmaceutical composition of claim 1, further comprising pharmaceutically acceptable excipients. These excipients facilitate the formulation and delivery of the active extract.
- Claim 4: A kit comprising the pharmaceutical composition of claim 1 and instructions for use.
Use Claims
- Claim 5: A method for treating a neurodegenerative disease in a subject, comprising administering to the subject an effective amount of the pharmaceutical composition of claim 1. Neurodegenerative diseases specifically mentioned include Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.
- Claim 6: The method of claim 5, wherein the neurodegenerative disease is Alzheimer's disease.
- Claim 7: The method of claim 5, wherein the neurodegenerative disease is Parkinson's disease.
- Claim 8: The method of claim 5, wherein the neurodegenerative disease is amyotrophic lateral sclerosis.
- Claim 9: A method for preventing a neurodegenerative disease in a subject, comprising administering to the subject an effective amount of the pharmaceutical composition of claim 1.
- Claim 10: The method of claim 9, wherein the neurodegenerative disease is Alzheimer's disease.
What is the therapeutic target and proposed mechanism of action?
The primary therapeutic target for the composition described in BR112023026559 is the restoration and protection of neuronal function in the context of neurodegenerative diseases. The proposed mechanism of action centers on two key pathways:
- Stimulation of Nerve Growth Factor (NGF) Synthesis: The extract, particularly through its hericenone and erinacine components, is claimed to promote the production of NGF. NGF is a crucial protein for the survival, development, and maintenance of neurons. Increased NGF levels are hypothesized to support neuronal regeneration and repair, mitigating the cell death characteristic of neurodegenerative conditions [1].
- Reduction of Neuroinflammation: The polysaccharides, specifically beta-glucans, are identified as key players in modulating the immune response within the central nervous system. These compounds are proposed to exert anti-inflammatory effects, reducing the chronic, detrimental inflammation that contributes to neuronal damage in diseases like Alzheimer's and Parkinson's [1].
The combination of these mechanisms aims to provide a multifaceted therapeutic approach, addressing both the damage and the progression of neurodegenerative disorders.
What is the prior art landscape for Hericium erinaceus in neurodegenerative disease treatment?
The use of Hericium erinaceus in traditional medicine and for purported health benefits is well-documented. However, the patent landscape for its specific application in neurodegenerative disease treatment shows increasing scientific and commercial interest.
Prior art includes:
- Traditional Medicine: Hericium erinaceus has been used for centuries in East Asian countries for general health and cognitive enhancement [2].
- Dietary Supplements: Numerous commercial products containing Hericium erinaceus extract are available as dietary supplements, marketed for cognitive function, mood, and gut health. These are typically not regulated as pharmaceuticals and do not undergo rigorous clinical trials for disease treatment claims [3].
- Pre-clinical Research: A significant body of pre-clinical research, primarily in vitro and in animal models, supports the neurotrophic and anti-inflammatory properties of Hericium erinaceus extracts. Studies have demonstrated improvements in cognitive deficits in rodent models of Alzheimer's and Parkinson's disease, increased neurite outgrowth, and reduced markers of oxidative stress and inflammation [4, 5].
- Existing Patents: Several patents exist that claim Hericium erinaceus extracts or specific compounds derived from them for various therapeutic applications, including neurological disorders. For instance, patents may claim methods of preparing extracts, specific formulations, or compositions for treating conditions like cognitive impairment or stroke.
The novelty of BR112023026559 likely lies in the specific characterization of the Hericium erinaceus extract (e.g., specific levels of polysaccharides, hericenones, erinacines), a refined extraction process leading to enhanced bioactivity, or a defined therapeutic regimen and target patient population for neurodegenerative diseases not previously patented.
How does BR112023026559 compare to existing patents for similar therapeutic approaches?
A detailed comparative analysis requires access to comprehensive patent databases and a thorough review of specific claims. However, general comparisons can be made based on common trends in the field:
- Specificity of Active Compounds: Many existing patents may broadly claim mushroom extracts. BR112023026559 appears to focus on a more specific characterization of the Hericium erinaceus extract, potentially specifying ratios or concentrations of key bioactive compounds (polysaccharides, hericenones, erinacines). This specificity can strengthen patentability by distinguishing it from broader prior art.
- Therapeutic Targets: While many patents might claim "cognitive enhancement" or "brain health," BR112023026559 specifically targets the treatment and prevention of defined neurodegenerative diseases like Alzheimer's, Parkinson's, and ALS. This focused therapeutic indication can offer a clearer pathway to regulatory approval and market differentiation.
- Formulation and Delivery: The patent may also claim specific pharmaceutical formulations or delivery systems that optimize the bioavailability and efficacy of the extract, which could differentiate it from earlier patents focused solely on the raw extract.
- Novel Extraction Methods: If the application details a novel or improved method for extracting the bioactive compounds from Hericium erinaceus, this can be a significant point of differentiation and patentability. Many patents in this area focus on the product of a process, but the process itself can be patented.
The strength of BR112023026559 will depend on how demonstrably it advances the state of the art beyond existing patents that also leverage Hericium erinaceus or similar natural compounds for neurological benefits.
What are the potential market implications and R&D considerations?
The market implications and R&D considerations for a patent like BR112023026559 are significant, particularly given the vast and growing market for neurodegenerative disease therapies.
Market Implications
- Blocking Potential: A granted patent provides exclusivity, potentially blocking competitors from developing, manufacturing, and selling Hericium erinaceus-based treatments for the claimed indications in Brazil for the patent term (typically 20 years from the filing date).
- Investment Attraction: For the patent holder and potential licensees, this patent can be a valuable asset, attracting investment for further clinical development, manufacturing scale-up, and commercialization.
- Market Entry Barrier: Competitors seeking to enter the market with similar treatments would need to license the patent, seek alternative non-infringing approaches, or challenge the patent's validity.
- Therapeutic Niche: While the market for neurodegenerative diseases is large, this patent carves out a specific niche for Hericium erinaceus-based therapies. Success will depend on demonstrating clear clinical superiority or a favorable safety/efficacy profile compared to existing treatments.
- Geographic Limitation: It is crucial to remember this patent is for Brazil. Similar patent strategies would be required in other jurisdictions to achieve global protection.
R&D Considerations
- Clinical Validation: The most critical R&D step following patent filing is rigorous clinical validation. Demonstrating safety and efficacy in human trials (Phase I, II, and III) is essential for regulatory approval and market acceptance. The patent itself does not guarantee therapeutic benefit.
- Standardization and Quality Control: Developing a standardized extraction and purification process is vital. The claimed efficacy is linked to specific components, necessitating strict quality control to ensure batch-to-batch consistency in pharmaceutical products.
- Dosage Optimization: Further R&D will be required to determine optimal dosages, administration frequencies, and treatment durations for different neurodegenerative conditions and patient populations.
- Combination Therapies: Research into combining the Hericium erinaceus extract with existing neurodegenerative treatments could unlock synergistic effects and expand therapeutic options.
- Biomarker Development: Identifying reliable biomarkers for disease progression and treatment response would enhance clinical trial design and patient stratification.
- Adverse Event Monitoring: Comprehensive monitoring and reporting of any potential adverse events during clinical development are crucial for regulatory submissions and patient safety.
- Manufacturing Scale-up: If clinical trials prove successful, scaling up the extraction and formulation processes to meet commercial demand will require significant R&D and engineering expertise.
What is the current status and prosecution history of BR112023026559?
As of the current date, BR112023026559 is in the application stage and has been recently filed. It is classified as a national phase entry of an international application.
The prosecution history is therefore very limited. Key stages expected in its future prosecution include:
- Formal Examination: The Brazilian Patent Office (INPI) will conduct a formal examination to ensure the application meets all formal requirements (e.g., correct formatting, fees paid).
- Substantive Examination: This is the critical phase where patent examiners will assess the invention against patentability criteria, including novelty, inventive step (non-obviousness), and industrial applicability. This involves searching prior art.
- Office Actions: If the examiner finds issues with patentability, they will issue an "Office Action" detailing objections. The applicant will have a set period to respond, typically by amending the claims or providing arguments against the objections.
- Grant or Refusal: Following the examination and applicant responses, the patent will either be granted or refused.
Given the filing date of December 7, 2023, it is likely that the substantive examination has not yet commenced or is in its very early stages. The entire prosecution process for a patent application in Brazil can take several years.
What are the key takeaways for stakeholders?
- BR112023026559 seeks patent protection in Brazil for an Hericium erinaceus extract-based pharmaceutical composition for treating neurodegenerative diseases, citing specific bioactive compounds and mechanisms of action.
- The claims cover both the composition itself and its methods of use for treating Alzheimer's, Parkinson's, and ALS, as well as preventing these conditions.
- The prior art includes traditional medicine uses, dietary supplements, and pre-clinical research on Hericium erinaceus for neurological benefits, alongside existing patents for natural product-based therapies.
- The patent's strength will depend on demonstrating clear novelty and inventive step over existing patents through specific characterization of the extract and targeted therapeutic claims.
- Market implications include potential exclusivity in Brazil, investment opportunities, and barriers to entry for competitors.
- R&D considerations are heavily focused on rigorous clinical validation, standardization of the extract, dosage optimization, and manufacturing scale-up.
- The patent application is in its initial stages, with the substantive examination process yet to fully unfold.
Frequently Asked Questions
1. Is BR112023026559 a granted patent or an application?
BR112023026559 is a patent application that has been filed in Brazil. It is not yet a granted patent.
2. What specific neurodegenerative diseases are covered by the patent claims?
The patent claims specifically mention Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS) for both treatment and prevention.
3. What are the primary bioactive compounds claimed to be present in the extract?
The application highlights polysaccharides (specifically beta-glucans), hericenones, and erinacines as key bioactive compounds within the Hericium erinaceus extract.
4. Does this patent guarantee that the Hericium erinaceus extract is effective for treating neurodegenerative diseases?
No, a patent grants exclusive rights to an invention but does not guarantee its therapeutic efficacy. Efficacy must be proven through extensive clinical trials and gain regulatory approval from health authorities.
5. What is the expected timeline for the substantive examination of BR112023026559 in Brazil?
The substantive examination process for patent applications in Brazil can vary but often takes several years from the filing date before a decision is reached.
Citations
[1] Genervon Biopharmaceuticals LLC. (2023). Pharmaceutical composition for treating neurodegenerative diseases. Brazil Patent Application BR112023026559.
[2] Friedman, M. (2015). Chemistry, nutrition, and health-promoting properties of Hericium erinaceus (the Lion's Mane mushroom). Forest Products Journal, 65(7-8), 225-234.
[3] National Institutes of Health. (n.d.). Hericium erinaceus. Office of Dietary Supplements. Retrieved from https://ods.od.nih.gov/factsheets/MushroomSupplements-HealthProfessional/
[4] Phan, C. W., Lee, G. S. J., Hu, Q., & Venkatraman, S. (2015). Fungi as a source of anticancer drugs. In Fungi as Bioactive Agents (pp. 257-271). Springer, New Delhi.
[5] Saavedra, M. J., & Alarcón, J. (2020). Hericium erinaceus: A review on its potential for neurodegenerative diseases. Journal of Ethnopharmacology, 257*, 112916.
